Michael Patrone

• A commercial-stage biopharmaceutical company with its USD3.9 billion sale to a global science and technology company
• A medical risk-assessment company with its pending sale to an asset management company in an all-stock transaction that values the company at approximately USD1.34 billion
• An enterprise software company with its USD1.7 billion sale to a global private equity firm and a sovereign wealth fund
• A clinical-stage biopharmaceutical company with its USD13.1 billion sale to a global biopharmaceutical company
• A global biopharmaceutical company with its acquisition of a global pharmaceutical and healthcare corporation’s biosimilars business for cash and stock valued at approximately USD3.335 billion
• A cloud communications company with its acquisition of a cloud-based customer communication platform in an all-stock transaction valued at approximately USD3 billion
• A genomic profiling company with its USD5.3 billion sale to a Swiss multinational holding healthcare company
• A software company in its strategic partnership with an industrial automation and digital technology company, and in securing a USD1 billion equity investment
• A virtual imaging technology company with its USD218 million sale to a leading manufacturer of display technologies
• Investors in a SaaS company for the investment management industry, with the company’s USD1.5 billion sale to a SaaS fintech company and related USD30 million tax receivable agreement (TRA) buyout
• Investors in a web application security company with the company’s USD775 million sale to a cloud computing company
• A SaaS fintech company with its TRA buyout
• A private equity firm with its USD1.6 billion take-private acquisition of a computer security company
• A leading multinational information technology company in the USD7 billion spin-off and merger of its enterprise services business with a multinational IT services corporation to form a multinational IT services and consulting company
• A medical technology company with the sale of its blood screening business for USD1.85 billion to a global healthcare company
• A timeshare company with its USD2.2 billion sale to a leading asset management firm
• A multinational company that operates, franchises, and licenses lodging brands in its USD12.2 billion acquisition of a global hospitality company
• A biopharmaceutical company with its abandoned USD54.8 billion sale to a pharmaceutical company
• A German private multinational conglomerate and a major book publishing company in the merger of the publishing company with a leading global publishing company
• A Chinese multinational conglomerate with its USD2.6 billion acquisition of a leading movie theater chain

SPAC transactions and reverse mergers

• A clinical-stage biopharmaceutical company with its strategic review process and take-private by a US life sciences company
• A clinical-stage biotechnology company with its business combination with another clinical-stage biotechnology company
• A digital therapeutics company with its business combination with a SPAC
• A SPAC in a transaction valued at approximately USD1.6 billion
• An additive manufacturing company with its business combination with a SPAC in a transaction valued at approximately USD2.1 billion
• A healthcare SPAC with its business combination with a biotechnology company in a transaction valued at approximately USD1.1 billion
• A value-based primary care provider with its business combination with a SPAC in a transaction valued at approximately USD5.9 billion
• Existing investors in an AI-powered accounts receivable company with its business combination with a SPAC in a transaction valued at approximately USD2.5 billion
• A clinical-stage biopharmaceutical company with its business combination with a SPAC in a transaction valued at approximately USD1 billion
• A SPAC with its de-SPAC process
• Investors in a biotechnology company’s business combination with a SPAC in a transaction valued at approximately USD17.5 billion
• Investors in a radiopharmaceutical company’s business combination with a SPAC in a transaction valued at approximately USD924 million

Financial institutions

• A hydrocarbon exploration company’s USD22.5 billion sale to an oil and gas company
• A financial technology corporation’s USD4.5 billion sale to a private investment firm
• A private equity investor firm’s USD1.1 billion acquisition of its external manager, a financial advisory firm
• A leading global satellite operator’s USD5 billion low-Earth orbit satellite project
• A major energy company’s USD9.1 billion acquisition of a diversified energy holding company